Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
25 results
D2.545 - Perception of adult patients in an allergy clinic after using Scribe artificial intelligence, our experience
D2.546 - Ethical Impact of Generative AI in Clinical Practice for Asthma and Allergy
D2.547 - The Transparent and Credible AI for Clinical Protocols
D2.548 - Expert Evaluation of Dialogue Quality and Clinical Reasoning in a Hybrid Multilingual LLM–Algorithm Allergy Decision-Support System: A Pilot Study of 34 Real-World Cases
D3.440 - Long-Term Efficacy and Safety of Donidalorsen for Hereditary Angioedema Among Patients in Europe: A Regional Analysis of the OASISplus Study
D3.441 - Switching to Donidalorsen for Hereditary Angioedema: 1-Year Results From the Phase 3 OASISplus Study
D3.444 - Efficacy and Safety of Donidalorsen for Patients With Hereditary Angioedema in Europe Who Switched From Prior Long-Term Prophylaxis: Results From the OASISplus Study
D3.445 - Validation of a Novel Serum-Based Indirect Basophil Activation Test (iBAT) to Evaluate Efficacy of a Pivotal Phase III PQ Grass Immunotherapy Trial
D3.437 - Impact of benralizumab on fatigue and health-related quality of life in patients with hypereosinophilic syndrome: findings from the NATRON phase 3 trial
D3.438 - Clinical outcomes with navenibart according to baseline attack rate, body mass index, and age: results of the ALPHA-STAR trial
D3.439 - Donidalorsen For The Treatment Of Hereditary Angioedema: 1-Year Results From The OASISplus Open-Label Extension Cohort
D3.442 - Patient-Reported Outcomes With Long-Term Donidalorsen Treatment Among Patients In Europe With Hereditary Angioedema: 1-Year Interim Results From The OASISplus Open-Label Extension Cohort
D3.443 - Patient-Reported Outcomes With Long-Term Donidalorsen Treatment Among Patients In Europe With Hereditary Angioedema: 1-Year Interim Results From The OASISplus Switch Cohort
D3.446 - PROTECT Phase I/IIa Clinical Trial Demonstrated Strong Correlation Between Humoral Immune Response and Dose of VLP Peanut in Healthy Participants
D3.447 - Pre-clinical Toxicology and Immunogenicity Evidence as a Precursor of the Successful Phase I/IIA Study with VLP Peanut
D3.448 - Use of Sebetralstat as Short-term Prophylaxis for Patients with Hereditary Angioedema: Results from the KONFIDENT-S Study
- D3.519 - Post-COVID-19 Reshaping of Molecular IgE Sensitization Profiles to Seasonal and Indoor Allergens
- D3.520 - Post-COVID Olfactory and Taste Dysfunction in Students at a South African Medical School
D3.521 - Dermatologic adverse effects of COVID-19 vaccination
- D3.522 - Post-Vaccination SARS-CoV-2 Infections: Evidence, Severity, and Outcomes
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download